
Your AI Hiring Tool Might Be Racist. Here Are Three Ways To Address AI Bias And Make Hiring More Fair
A 2024 Bloomberg analysis revealed racial bias in OpenAI's ChatGPT 3.5. According to a Business Insider report, researchers used ChatGPT to screen resumes for jobs, with their analysis indicating that the AI tool over-selected Asian women job applicants and under-selected Black men job applicants. In a separate Australian study, researcher Natalie Sheard demonstrated that the AI tools used during the hiring process penalized non-native English speakers with accents from other countries more than English-language speakers in the U.S. The Australian human resource professionals interviewed indicated that curriculum vitae analysis systems and video interview systems were common AI tools used to evaluate job candidates. Many companies use facial analysis and recognition software to make workplace decisions, but these tools can exacerbate existing racial disparities.
There are a few different reasons why bias creeps into the AI tools used for hiring. The first is faulty training data. According to IBM, machine learning that is trained on samples that are homogenous and lack diversity will reproduce bias. In the aforementioned Australian study, the researcher noted another way bias can creep into these systems: an algorithmic model may prioritize characteristics and traits that are typically associated with dominant cultural norms, disadvantaging non-white job candidates and those with less traditional backgrounds and characteristics. IBM argues that when humans are programming AI models, our biases can seep into these models and show up in ways like exclusion bias; AI models also learn and replicate societal biases, which can show up as stereotyping bias.
AI hiring tools that end up causing bias can be a costly mistake for employers. Here's how companies can address biases in AI hiring tools:
1. Require audits of AI tools. Under New York City's Automated Employment Decision Tools Law, which went into effect in July 2023, employers are prohibited from using 'automated employment decision tools' to make hiring and promotion decisions unless an independent auditor reviews the tool before usage. Under the law, job candidates are also required to receive notice that the tool is being used. Organizations should follow similar guidelines and consider implementing AI tools to make hiring decisions only after an outside review from an auditor.
2. Assess AI tool over time. After making the decision to implement AI hiring tools into the workplace, these tools should be continuously monitored over time. A 2025 article from Peoplebox.ai suggests that in order to get the most out of your AI tool, consistent checks are imperative. Assess important metrics to ensure AI tools are addressing the issues they were adopted for. Some questions the article suggests considering: 'Has AI helped you hire faster? Are your new hires performing better? Is the candidate's experience improving?' Also evaluate whether job candidates from certain backgrounds are being filtered out by the AI tool and manually assess these candidates to ensure fairness in the process.
3. Don't rely solely on AI tools. There should be some oversight when deploying AI hiring tools and companies shouldn't rely on these tools to make the final hiring decisions. Employees that will be engaging with these tools should receive adequate and thorough training on ethical use and deployment of AI tools. Trust (to an extent) but verify, when it comes to workplace AI tools. It's important to remember that AI cannot replace humans in the hiring process.
We must remember that no workplace tool will ever be perfect. AI is not a panacea for recruitment and hiring issues and should be implemented with care, concern and consideration. AI is revolutionizing our workplaces in a plethora of ways and in the years to come, AI in our workplaces will be inevitable. While the possibilities of these tools seem endless, we must also be mindful of their vulnerabilities and limitations.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Pfizer battles another Paxlovid lawsuit from Enanta
If you don't succeed at first, try again – in separate regions. That's the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir). In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders. However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means. The US biotech stated it is 'seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's Covid-19 antiviral, Paxlovid'. In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: 'We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.' The lawsuit, filed in the European Union's (EU) Unified Patent Court (UPC), targets Pfizer's commercial activity in the 18 countries of the EU. The company confirmed the '265 patent in question is the European counterpart of US patent number 11,358,953 (the '953 Patent) that is the centre of the US lawsuit. Although it is technically ongoing, Enanta's US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the '953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it 'believes strongly in the merits of our case'. Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%. However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022. "Pfizer battles another Paxlovid lawsuit from Enanta" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Nasdaq slides again as AI jitters rattle tech investors
NEW YORK (Reuters) -Tech stocks are leading declines on Wall Street, with worries about AI spurring debates about its future. The Nasdaq Composite is down around 2.4% over the last two days, the worst two-day fall since April. The semiconductor index was down 1.5%, while the information technology sector was the second biggest decliner in the S&P 500, dropping 1.1% on Wednesday. Market participants attributed the selloff to a range of factors including a technical pullback after driving much of the stock market's recovery in the weeks after April 2nd "Liberation Day." Analysts also cited deepening concerns of government interference with companies, as the Trump administration looked into taking equity stakes in chip companies such as Intel in exchange for grants under the CHIPS Act. COMMENTS: ART HOGAN, MARKET STRATEGIST, B. RILEY WEALTH MANAGEMENT, BOSTON: "Technology in general is up 40% from its April lows, and the group clearly got ahead of itself. Also, if there's anything to the market consensus that we'll see a Fed rate cut, then there will be room for other things to work as well – and there are 493 other stocks in the S&P 500 that are lagging the Mag 7 right now. So I think there's a bit of a rotation." "I don't know how long it will last, but if it does keep going, well, August and September (are) the weak period seasonally in which it could do so. Also, there are some people who are beginning to question the pace at which we need to be chasing AI capital spending. If you put all this together: when technology stocks take a breather, this is what it looks like. Nvidia and other blue chips in the group are seeing relatively steady drawdowns, but things on the speculative edge are clearly seeing more selling pressure. Palantir has gone from trading at 200 times sales to 150 times its sales, for instance." MICHAEL ASHLEY SCHULMAN, CHIEF INVESTMENT OFFICER, RUNNING POINT, EL SEGUNDO, CALIFORNIA: "Tuesday' s U.S. technology stock swoon and its continuation today looks like multiple compression meeting a little margin math, but the timing makes it hard to ignore the new elephant in the server room. Names that had been sprinting on AI dreams pulled back hard, with Nvidia, AMD, and Palantir Technologies among the drags." "DeepSeek's update landed on Tuesday represents a serious cocktail of capability and availability and traders well remember the original harsh tech-market pullback DeepSeek caused when it was first broadly recognized in January of this year." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, BROOKFIELD, WISCONSIN: "When you go from rally to rout, it shows how vulnerable the names were to even a scent of bad news. It could have been (Sam)Altman's valuation warning and then Meta restructuring its AI division threw fuel on the fire." PHIL BLANCATO, CHIEF EXECUTIVE OFFICER, LADENBURG THALMANN ASSET MANAGEMENT, NEW YORK: "It's much more about profit-taking and temporary rebalancing here. If you get a Federal Reserve cut or a mention of it on Friday, this will reverse pretty quickly, but this is a lot to do with names pushed up to really lofty levels and profit taking across the board." SETH HICKLE, PORTFOLIO MANAGER, MINDSET WEALTH MANAGEMENT, INDIANAPOLIS: "I think we are starting to see a little bit of rotation. It's always healthy to see a little bit of a pullback to that way, the markets can kind of get re-oriented." "To me, tech was overbought. Maybe it was justified, but it could have been kind of a buy on the rumor, sell it on the news type of thing where we had tech runup into earnings. We had really good earnings, and now it's kind of natural for the market just to sell some of that good news." "I wouldn't be surprised if we see a little bit of rotation into some smaller cap or into healthcare names, or consumer staples. And to me, that's kind of a healthy rotation. But honestly, I don't believe it will be a longer-term trend. It'll probably be a shorter-term trend. I think we'll see money flow back into tech in the next couple months." STEVE SOSNICK, CHIEF STRATEGIST, INTERACTIVE BROKERS, CONNECTICUT "The tech-led selloff that we saw yesterday resumed this morning. That said, dip buyers stepped in around 11am EDT and we've now recovered about half our losses. It's somewhat inevitable to expect them to arrive promptly, though it did take a bit longer than usual." "I believe that some of the early declines are related to profit-taking and risk squaring ahead of (Fed Chair Jerome)Powell's speech on Friday. That is merely rotation and relatively benign, though it gets magnified because of megacap tech stocks' heavy weighting in key indices. But some of the ferocity of the early drop was related to the President's calls for Lisa Cook's resignation." "Note that futures broke through their pre-market lows shortly after he posted on Truth Social. Markets were not perturbed that there are inquiries into the propriety of her personal mortgage applications. She gets a presumption of innocence until proven guilty, like any other person. But when the President weighed in even before the process began, then it raised the specter of politicization. That put markets on the wrong foot early, and negative momentum ruled again – at least for a couple of hours." ADAM SARHAN, CHIEF EXECUTIVE, 50 PARK INVESTMENTS, NEW YORK: "To see a little pullback here after a big move up is perfectly normal and healthy. If the selling gets worse then you'll see a rotation out of tech and into undervalued areas of the market like biotech stocks or healthcare stocks or small cap stocks because those areas have not participated this year." Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Info-Tech LIVE IT Conference for the APAC Region Returns to Brisbane, Australia, March 2026
Info-Tech Research Group, a global research and advisory firm, has announced the return of its premier IT conference, Info-Tech LIVE, to Brisbane, Australia, on March 17-18, 2026. Following a highly successful debut in 2025, the event's second annual APAC edition will once again deliver exclusive insights, high-value networking opportunities, and direct engagement with industry-leading analysts and experts, all under the guiding theme, "Transform IT. Transform Everything." TORONTO, Aug. 20, 2025 /PRNewswire/ - Info-Tech Research Group, a global leader in IT research and advisory, has confirmed that its flagship global IT conference, Info-Tech LIVE, will return to Brisbane March 17-18, 2026, for the second consecutive year. Hosted at the iconic W Brisbane, the two-day event will continue to serve as the APAC region's go-to destination for CIOs, senior IT executives, and technology leaders seeking actionable strategies to navigate the exponentially evolving technology landscape. Building on the momentum of the inaugural 2025 event, which brought together hundreds of CIOs and IT professionals from across Australia, New Zealand, and the wider Asia-Pacific, Info-Tech LIVE 2026 in Brisbane will feature a tactical, hands-on agenda designed by experienced industry experts and practitioners. Attendees will gain practical tools and strategies to address real-world challenges, improve IT-business alignment, and prepare their organizations to capitalize on emerging opportunities. "The success of our first Brisbane event showed just how valuable a region-specific forum can be for technology leaders in the Asia-Pacific," says George Khreish, managing partner at Info-Tech Research Group, APAC. "Our return in 2026 is about building on that momentum and providing an even stronger support platform for CIOs and IT leaders in the region to collaborate, gain new perspectives, and leave with practical strategies to drive meaningful change in their organizations." As one of Australia's fastest-growing technology hubs, Brisbane offers a dynamic environment for innovation, making it an ideal location for fostering collaboration and advancing strategic IT priorities in the APAC region. "Info-Tech LIVE in Brisbane has already established itself as a cornerstone event for technology leaders in the region," says Vice President Byron Rudenno of Info-Tech Research Group, APAC. "It's an opportunity to bring the world's best research and global insights directly to our local market, while creating a space for Australian and Asia-Pacific IT leaders to tackle shared challenges with international best practices, exchange ideas, and prepare to lead in an era of exponential technological change reshaping industries." With a continued focus on the theme "Transform IT. Transform Everything," Info-Tech LIVE 2026 in Brisbane will examine the role of IT as the driver of enterprise-wide innovation. Key sessions will cover how exponential technologies can disrupt entire industries and how IT leaders can translate these shifts into tangible business results. The agenda will feature mainstage keynotes, interactive breakouts, lightning rounds on emerging opportunities in the space, and the event's popular one-on-one analyst meetings tailored to attendees' unique priorities. For more information about the event, please visit Info-Tech's LIVE media kit page. Further details on the agenda, keynote speakers, and registration will be announced in the coming months. Follow Info-Tech Research Group on LinkedIn and X for updates. Media Passes for Info-Tech LIVE in Brisbane, March 17-18, 2026Media professionals, including journalists, podcasters, and influencers, are invited to attend Info-Tech LIVE 2026 in Brisbane to gain exclusive access to research, content, and interviews with industry leaders for their audiences. Media professionals can apply for complimentary in-person passes by contacting pr@ About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software-buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@ View original content to download multimedia: SOURCE Info-Tech Research Group Sign in to access your portfolio